Carl Jacobsens Vej 30
Valby
Copenhagen 2500
Denmark
45 70 20 27 28
https://www.genmab.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 2,204
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, President & CEO | 2.88M | N/A | 1961 |
Mr. Anthony Pagano | Executive VP & CFO | 1.02M | N/A | 1978 |
Ms. Birgitte Stephensen M.Sc. | Executive VP & Chief Legal Officer | 632.98k | N/A | 1961 |
Dr. Martine J. van Vugt Ph.D. | Executive VP & Chief Strategy Officer | 690.52k | N/A | 1971 |
Mr. Martin Schultz | Senior Director of Clinical Operations & Non-Independent Director | 115.09k | N/A | 1976 |
Dr. Tahamtan Ahmadi | Executive VP, Chief Medical Officer & Head of Experimental Medicines | 1.11M | N/A | 1973 |
Dr. Mijke Zachariasse Ph.D. | Senior Director, Head of Antibody Research Materials & Non-Independent Director | 158.24k | N/A | 1974 |
Mr. Takahiro Hamatani | Senior Director of Finance Japan & Non-Independent Director | 115.09k | N/A | 1975 |
Mr. Anthony Mancini | Executive VP & COO | 1.09M | N/A | 1971 |
Mr. Andrew Carlsen | Senior Director, VP & Head of Investor Relations | N/A | N/A | N/A |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S’s ISS governance QualityScore as of 1 May 2024 is 3. The pillar scores are Audit: 1; Board: 1; Shareholder rights: 1; Compensation: 9.